← Back to Portfolio

Intellikine

Intellikine developed small molecule therapies targeting the PI3K/mTOR pathway for treatment of cancer, inflammation and autoimmune diseases. The company was acquired by Takeda for up to $310 million in January 2012.

Location San Diego, California